Advancements that could lead to earlier diagnosis and treatment for diabetic retinopathy, a common complication that affects the eyes, have been identified by a multi-department research team from Michigan State and other universities.
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NN-9931?
NN-9931 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH).
April 17, 2024